More stories

COMPASS Pathways is granted new US patent for crystalline psilocybin

London, UK – 19 October 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based...

atai Life Sciences Launches atai Impact, a Philanthropic Program to Harness the Power of...

NEW YORK and BERLIN, Oct. 19, 2021 (GLOBE NEWSWIRE) — atai Life Sciences (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company, today announced the launch...

Mycrodose Therapeutics and Nova Mentis Announce LOI to Co-Develop Advanced Drug Delivery System

Partnership will Create Patented Products for the Treatment of Neuroinflammatory Disorders VANCOUVER, BC, Oct. 19, 2021 /CNW/ – October 19, 2021 – Nova Mentis...

Field Trip Health Ltd. Continues Expansion With Psychedelic-Assisted Therapy Centers in Seattle, Vancouver and...

With the Opening of Three New Clinics, Field Trip Health Builds Momentum for the Psychedelic Renaissance in the Mental Health Field TORONTO, Oct. 19,...

Psyched Wellness Announces Preliminary Data Showing Potential New Functional Property and Health Benefit of...

Toronto, Ontario–(Newsfile Corp. – October 19, 2021) – Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the “Company” or “Psyched“) a life sciences...

Cybin Announces Completion of 74 Pre-Clinical Psychedelic Molecule Studies

–The Company expects to hold a Research & Development event to review these breakthrough findings in Q4 2021 that will be open to the...

First Patient Dosed in Phase IIa DMT-Assisted Therapy Clinical Trial

Phase IIa to explore the effectiveness of DMT in combination with psychotherapy for the potential treatment of Major Depressive Disorder Program remains on track...

PT267 – Rebecca Kronman, LCSW – Psychedelics, Pregnancy, and Parenthood

In this episode, Joe Moore interviews Rebecca Kronman, LCSW: Brooklyn-based therapist offering ketamine-assisted psychotherapy, writer, and founder of Plant Parenthood: a digital platform investigating...

Psychedelic Research Bulletin: September 2021

September brought nearly 30 new and exciting papers on psychedelics. Some publications focus on their safety, such as one that looks at LSD in...

Psychedelic Bulletin: atai Launches Precision Psychiatry Company; DEA Proposes Further Increase to Psychedelics Production...

Earlier this week, atai Life Sciences announced the launch of PsyProtix, which aims to develop a precision psychiatry approach for Treatment-Resistant Depression (TRD). The...

PTSF81 – Somatics, Reframing Trauma, and the 7 Lens Approach, with Liam Farquhar

In this week’s Solidarity Fridays episode, Kyle Buller speaks with integration specialist, past Navigating Psychedelics student, and Netherlands-based legal psychedelic guide, Liam Farquhar. Farquhar...

MindMed Joins Clinical Trials Transformation Initiative

NEW YORK, Oct. 13, 2021 /CNW/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the “Company”), a leading biotech company developing...

Most popular